Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy

Michael Diestelhorst, Jean Philippe Nordmann, Carol B Toris

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Adjunctive intraocular pressure (IOP)-lowering therapy is widely used today, as one-third of all patients being treated for glaucoma need additional therapy to reach and maintain healthy IOPs. Timolol, latanoprost, and pilocarpine are three potent drugs that have been used in combination to reduce IOP. Timolol reduces the production rate of aqueous humor to achieve the IOP decrease. Latanoprost and pilocarpine both affect aqueous outflow, although by different mechanisms. The IOP efficacy of combined therapy with timolol and pilocarpine compared with timolol and latanoprost or with latanoprost alone has been investigated in three multicenter, randomized, clinical trials in Europe. This is a review of those published trials. In 2 of the 3 studies, the additional IOP lowering effect of latanoprost 0.005% administered once daily was compared with pilocarpine 2% administered 3 times daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension currently on monotherapy with timolol 0.5% twice daily. These 6-month studies found that the timolol and latanoprost combination reduced IOP more and was better tolerated with fewer side-effects than the timolol and pilocarpine combination. At 6 months, there was no evidence of long-term drift in IOP with timolol and latanoprost. This combined therapy provides an effective and safe option for lowering IOP in glaucoma patients. These results suggest that the timolol/latanoprost combination is preferable to the timolol/pilocarpine combination not only with regard to side effects but also to the magnitude of IOP reduction. Two of the 3 studies compared latanoprost monotherapy with timolol and pilocarpine combined therapy in patients with POAG, various other glaucomas, or ocular hypertension. Treatment was for 6 weeks or 6 months. In both studies, latanoprost was more effective and better tolerated than the combination of timolol and pilocarpine. These results suggest that latanoprost alone should be tried before the addition of pilocarpine to timolol therapy is considered. The convenience of daily administration of a single drop of latanoprost versus multiple drops of timolol and pilocarpine should improve patient compliance.

Original languageEnglish (US)
Pages (from-to)S155-S161
JournalSurvey of Ophthalmology
Volume47
Issue number4 SUPPL. 1
DOIs
StatePublished - Aug 2002

Fingerprint

latanoprost
Timolol
Pilocarpine
Intraocular Pressure
Therapeutics
Glaucoma
Ocular Hypertension

Keywords

  • Glaucoma
  • Intraocular pressure
  • Latanoprost pilocarpine
  • Prostaglandin analog
  • Timolol

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy. / Diestelhorst, Michael; Nordmann, Jean Philippe; Toris, Carol B.

In: Survey of Ophthalmology, Vol. 47, No. 4 SUPPL. 1, 08.2002, p. S155-S161.

Research output: Contribution to journalArticle

Diestelhorst, Michael ; Nordmann, Jean Philippe ; Toris, Carol B. / Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy. In: Survey of Ophthalmology. 2002 ; Vol. 47, No. 4 SUPPL. 1. pp. S155-S161.
@article{87951c31040f43419e5ef3faf0f93129,
title = "Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy",
abstract = "Adjunctive intraocular pressure (IOP)-lowering therapy is widely used today, as one-third of all patients being treated for glaucoma need additional therapy to reach and maintain healthy IOPs. Timolol, latanoprost, and pilocarpine are three potent drugs that have been used in combination to reduce IOP. Timolol reduces the production rate of aqueous humor to achieve the IOP decrease. Latanoprost and pilocarpine both affect aqueous outflow, although by different mechanisms. The IOP efficacy of combined therapy with timolol and pilocarpine compared with timolol and latanoprost or with latanoprost alone has been investigated in three multicenter, randomized, clinical trials in Europe. This is a review of those published trials. In 2 of the 3 studies, the additional IOP lowering effect of latanoprost 0.005{\%} administered once daily was compared with pilocarpine 2{\%} administered 3 times daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension currently on monotherapy with timolol 0.5{\%} twice daily. These 6-month studies found that the timolol and latanoprost combination reduced IOP more and was better tolerated with fewer side-effects than the timolol and pilocarpine combination. At 6 months, there was no evidence of long-term drift in IOP with timolol and latanoprost. This combined therapy provides an effective and safe option for lowering IOP in glaucoma patients. These results suggest that the timolol/latanoprost combination is preferable to the timolol/pilocarpine combination not only with regard to side effects but also to the magnitude of IOP reduction. Two of the 3 studies compared latanoprost monotherapy with timolol and pilocarpine combined therapy in patients with POAG, various other glaucomas, or ocular hypertension. Treatment was for 6 weeks or 6 months. In both studies, latanoprost was more effective and better tolerated than the combination of timolol and pilocarpine. These results suggest that latanoprost alone should be tried before the addition of pilocarpine to timolol therapy is considered. The convenience of daily administration of a single drop of latanoprost versus multiple drops of timolol and pilocarpine should improve patient compliance.",
keywords = "Glaucoma, Intraocular pressure, Latanoprost pilocarpine, Prostaglandin analog, Timolol",
author = "Michael Diestelhorst and Nordmann, {Jean Philippe} and Toris, {Carol B}",
year = "2002",
month = "8",
doi = "10.1016/S0039-6257(02)00329-6",
language = "English (US)",
volume = "47",
pages = "S155--S161",
journal = "Survey of Ophthalmology",
issn = "0039-6257",
publisher = "Elsevier USA",
number = "4 SUPPL. 1",

}

TY - JOUR

T1 - Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy

AU - Diestelhorst, Michael

AU - Nordmann, Jean Philippe

AU - Toris, Carol B

PY - 2002/8

Y1 - 2002/8

N2 - Adjunctive intraocular pressure (IOP)-lowering therapy is widely used today, as one-third of all patients being treated for glaucoma need additional therapy to reach and maintain healthy IOPs. Timolol, latanoprost, and pilocarpine are three potent drugs that have been used in combination to reduce IOP. Timolol reduces the production rate of aqueous humor to achieve the IOP decrease. Latanoprost and pilocarpine both affect aqueous outflow, although by different mechanisms. The IOP efficacy of combined therapy with timolol and pilocarpine compared with timolol and latanoprost or with latanoprost alone has been investigated in three multicenter, randomized, clinical trials in Europe. This is a review of those published trials. In 2 of the 3 studies, the additional IOP lowering effect of latanoprost 0.005% administered once daily was compared with pilocarpine 2% administered 3 times daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension currently on monotherapy with timolol 0.5% twice daily. These 6-month studies found that the timolol and latanoprost combination reduced IOP more and was better tolerated with fewer side-effects than the timolol and pilocarpine combination. At 6 months, there was no evidence of long-term drift in IOP with timolol and latanoprost. This combined therapy provides an effective and safe option for lowering IOP in glaucoma patients. These results suggest that the timolol/latanoprost combination is preferable to the timolol/pilocarpine combination not only with regard to side effects but also to the magnitude of IOP reduction. Two of the 3 studies compared latanoprost monotherapy with timolol and pilocarpine combined therapy in patients with POAG, various other glaucomas, or ocular hypertension. Treatment was for 6 weeks or 6 months. In both studies, latanoprost was more effective and better tolerated than the combination of timolol and pilocarpine. These results suggest that latanoprost alone should be tried before the addition of pilocarpine to timolol therapy is considered. The convenience of daily administration of a single drop of latanoprost versus multiple drops of timolol and pilocarpine should improve patient compliance.

AB - Adjunctive intraocular pressure (IOP)-lowering therapy is widely used today, as one-third of all patients being treated for glaucoma need additional therapy to reach and maintain healthy IOPs. Timolol, latanoprost, and pilocarpine are three potent drugs that have been used in combination to reduce IOP. Timolol reduces the production rate of aqueous humor to achieve the IOP decrease. Latanoprost and pilocarpine both affect aqueous outflow, although by different mechanisms. The IOP efficacy of combined therapy with timolol and pilocarpine compared with timolol and latanoprost or with latanoprost alone has been investigated in three multicenter, randomized, clinical trials in Europe. This is a review of those published trials. In 2 of the 3 studies, the additional IOP lowering effect of latanoprost 0.005% administered once daily was compared with pilocarpine 2% administered 3 times daily in patients with primary open-angle glaucoma (POAG) or ocular hypertension currently on monotherapy with timolol 0.5% twice daily. These 6-month studies found that the timolol and latanoprost combination reduced IOP more and was better tolerated with fewer side-effects than the timolol and pilocarpine combination. At 6 months, there was no evidence of long-term drift in IOP with timolol and latanoprost. This combined therapy provides an effective and safe option for lowering IOP in glaucoma patients. These results suggest that the timolol/latanoprost combination is preferable to the timolol/pilocarpine combination not only with regard to side effects but also to the magnitude of IOP reduction. Two of the 3 studies compared latanoprost monotherapy with timolol and pilocarpine combined therapy in patients with POAG, various other glaucomas, or ocular hypertension. Treatment was for 6 weeks or 6 months. In both studies, latanoprost was more effective and better tolerated than the combination of timolol and pilocarpine. These results suggest that latanoprost alone should be tried before the addition of pilocarpine to timolol therapy is considered. The convenience of daily administration of a single drop of latanoprost versus multiple drops of timolol and pilocarpine should improve patient compliance.

KW - Glaucoma

KW - Intraocular pressure

KW - Latanoprost pilocarpine

KW - Prostaglandin analog

KW - Timolol

UR - http://www.scopus.com/inward/record.url?scp=0036669532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036669532&partnerID=8YFLogxK

U2 - 10.1016/S0039-6257(02)00329-6

DO - 10.1016/S0039-6257(02)00329-6

M3 - Article

C2 - 12204713

AN - SCOPUS:0036669532

VL - 47

SP - S155-S161

JO - Survey of Ophthalmology

JF - Survey of Ophthalmology

SN - 0039-6257

IS - 4 SUPPL. 1

ER -